Sector
PharmaceuticalsOpen
₹2.19Prev. Close
₹2.15Turnover(Lac.)
₹4.16Day's High
₹2.19Day's Low
₹2.0552 Week's High
₹6.0852 Week's Low
₹1.9Book Value
₹1Face Value
₹1Mkt Cap (₹ Cr.)
8.36P/E
0EPS
0Divi. Yield
06 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
5 Jul 2024
12:00 AM
AGM
Announcement Date: 05 Jul, 2024
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 4 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 0.72 | 0.4 | -0.17 | -0.63 |
Net Worth | 4.72 | 4.4 | 3.83 | 3.37 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 9.14 | 9.22 | 9.42 | 6.44 |
yoy growth (%) | -0.82 | -2.18 | 46.4 | 85.35 |
Raw materials | -8.48 | -8.56 | -9.13 | -5.52 |
As % of sales | 92.71 | 92.83 | 96.88 | 85.85 |
Employee costs | -0.11 | -0.29 | -0.25 | -0.1 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 0.46 | 0.14 | -0.2 | 0.26 |
Depreciation | 0 | 0 | 0 | 0 |
Tax paid | 0 | -0.04 | 0 | -0.02 |
Working capital | 4.72 | 0.09 | -1.25 | 0.48 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -0.82 | -2.18 | 46.4 | 85.35 |
Op profit growth | -61.07 | -141.68 | -147.48 | -495.32 |
EBIT growth | 41.27 | 166.09 | -63.7 | -651.11 |
Net profit growth | 364.35 | -149 | -184.9 | -251.1 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 7.42 | 27.84 | 17.81 | 10.4 | 9.89 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 7.42 | 27.84 | 17.81 | 10.4 | 9.89 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 0.06 | 0.05 | 0.48 | 0.83 | 0.51 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.65 | 92.31 | 3,95,326.43 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,537.95 | 78.57 | 1,73,562.03 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,498.35 | 24.58 | 1,21,022.9 | 1,485.4 | 1.07 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,312.75 | 20.48 | 1,09,550.72 | 1,200.7 | 0.61 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,226.65 | 57.31 | 1,09,199.59 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Non Executive Director
Hemant Parikh
Managing Director
Jayendra Mehta
Independent Director
Rina Kumari
Independent Director
Shah A P
403 Sarthik 2 Opp Rajpath Club,
S G Highway,
Gujarat - 380054
Tel: 91-07405699869
Website: http://www.iveeinjectaa.com
Email: info@iveeinjectaa.com; info@vivanzabiosciences.com
9 ShivShakti Indl Es,
J R Boricha Marg, Lower Parel,
Mumbai - 400 011
Tel: 91-22-23016761/8261
Website: -
Email: -
Summary
Vivanza Biosciences Limited(Previously known Ivee Injectaa Limited) was established in March, 1982 as a Private Limited Company and was converted into a Public Limited Company in May, 1992. Due to rec...
Read More
Reports by Vivanza Biosciences Ltd
What is the Vivanza Biosciences Ltd share price today?
What is the Market Cap of Vivanza Biosciences Ltd?
What is the PE and PB ratio of Vivanza Biosciences Ltd?
What is the 52 Week High and Low of Vivanza Biosciences Ltd?
What is the CAGR of Vivanza Biosciences Ltd?
What is the shareholding pattern of Vivanza Biosciences Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.